Tag Archives: TTG
Alfacell Provides Update on ONCONASE Phase IIIb Confirmatory Registration Trial; Releases First Interim Analysis Data
Press Release from Alfacell Corporation April 27, 2006 BLOOMFIELD, N.J., April 27 /PRNewswire-FirstCall/ — Alfacell Corporation today announced that the 210 events (deaths) has been reached in its confirmatory Phase IIIb registration trial evaluating ONCONASE® (ranpirnase), the Company’s lead investigational drug candidate, as a treatment for unresectable malignant mesothelioma (UMM). This number of events represents [...]
Phase III Program ofONCONASE for The Treatment of Patients with Unresectable Malignant Mesothelioma
SOURCE: Alfacell Corporation BLOOMFIELD, N.J., April 3 /PRNewswire-FirstCall/ — Alfacell Corporation today announced that the encouraging survival data from its Phase II multicenter trial of ONCONASE®, led the Company to conduct a Phase III program which included the evaluation of ONCONASE as a single agent at 33 centers across the United States and the combination [...]
Results of the Phase II Multicenter Trial of ONCONASE(R) As a Single Agent
SOURCE: Alfacell Corporation Encouraging Survival in Patients With Advanced Malignant Mesothelioma Treated With Alfacell’s ONCONASE ® BLOOMFIELD, N.J., Jan. 22 /PRNewswire-FirstCall/ — Alfacell Corporation (OTC Bulletin Board: ACEL – news), today announced the publication of Phase II trial results of ONCONASE ®, a novel anti-cancer drug, in patients with unresectable, or inoperable, malignant mesothelioma (MM), [...]
ONCONASE Shows Survival Benefit in Patients with Malignant Mesothelioma
May 23, 2000–Alfacell Corporation announced today that preliminary survival results of our Phase III trial were presented at the 90th annual meeting of the American Society of Clinical Oncology (ASCO) in New Orleans, LA by Nicholas Vogelzang, M.D., Fred Buffet Professor of Medicine and Director of the University of Chicago Cancer Research Center, Chicago, Illinois. [...]
